Peptides have become a hot topic in medical spas, IV clinics, and wellness practices, particularly in connection with weight management, longevity, and anti-aging treatments. At the same time, peptides occupy a complex regulatory space that blends federal and state law, compounding restrictions and advertising oversight.
Recent public statements by Secretary of Health and Human Services Robert F. Kennedy Jr. criticizing federal health regulations have prompted renewed discussion about whether federal views on peptides may be shifting. For healthcare business owners, however, the key issue is not political messaging, but whether any enforceable legal standards have actually changed.
Current Regulatory Framework
From a legal perspective, peptides are generally regulated by the U.S. Food and Drug Administration (FDA) as drugs or biological products, depending on their structure and intended use. For a peptide to be lawfully prescribed, administered, or compounded for patients, it typically must:
- Be part of an FDA‑approved drug product;
- Be included in an applicable USP monograph; or
- Appear on an FDA bulks list permitting compounding under Section 503A or 503B of the Food, Drug, and Cosmetic Act.
Many peptides commonly discussed in medspa and wellness settings, including those marketed online for “research use only” purposes or marketed by influencers online, do not meet these criteria. Their popularity does not equal legality and providers should be aware that “research use only” peptides are not approved for use on human subjects outside of FDA-compliant research settings.
This is where many practices run into trouble: peptides may be widely advertised, discussed on social media, or offered by competitors, yet still fall outside what federal, and potentially state, law permits.
Commentary Versus Regulatory Action
Secretary Kennedy has publicly criticized what he views as excessive FDA control over healthcare innovation, including restrictions on peptides. In a widely circulated social media post, Kennedy said that the “FDA’s war on public health is about to end,” explicitly listing psychedelics, stem cells, and peptides among the therapies he believes the agency has “aggressively suppressed.” He has framed this critique as part of a broader agenda to reduce what he describes as regulatory capture by industry and to expand consumer access to a wider range of health interventions.
These public statements align with recent congressional attention to peptide regulation. In November 2025, U.S. Representative Andy Harris sent a letter to the Secretary of Health and Human Services urging the agency to exercise enforcement discretion with respect to certain peptides, citing concerns that existing regulatory approaches may be inhibiting research and patient access.
While these remarks signal his regulatory philosophy, they reflect personal commentary rather than binding changes to existing law, regulation or FDA policy.
As of now:
- There has been no formal FDA rulemaking expanding peptide-compounding eligibility.
- FDA guidance still treats most non‑approved peptides as ineligible for routine compounding.
- Enforcement authority remains unchanged, even if priorities fluctuate.
Any meaningful change would require concrete action, such as updated guidance, formal enforcement discretion memoranda, or legislative amendments. None of those steps have occurred to date.
For medspas and IV clinics, this distinction is critical. Operating based on perceived future policy, rather than current law, is one of the fastest ways to invite regulatory scrutiny.
Where Medspas and IV Clinics Face the Greatest Risk
Peptide-related scrutiny often arises alongside other compliance issues that regulators already watch closely in the medspa and wellness space.
1. Marketing and Advertising Claims
Even when peptides are labeled “research use only,” marketing them in a way that implies patient benefit, dosing, or treatment outcomes can trigger FDA scrutiny. Websites, social media posts, intake forms, and IV menus all matter.
2. Compounding and Prescribing Arrangements
Medspas frequently rely on third‑party compounding pharmacies. If a pharmacy compounds peptides that are not legally permitted, providers ordering and administering those products may invite scrutiny and possibly disciplinary action from state licensing boards. . Additionally, the surge in demand for peptides and lack of FDA regulation has created a gray market of online peptide distributors. This unregulated market creates quality control and supply chain issues that make it difficult to verify the source and quality of their peptides. Providers and businesses that are interested in providing peptides should order from established compounding pharmacies that can provide a certificate of analysis demonstrating the quality of the peptide product.
3. Medical Director and Scope‑of‑Practice Issues
Peptides are medical treatments rather than aesthetic or spa services. Inadequate medical director oversight, improper delegation, or insufficient clinical protocols can lead to state board investigations in addition to federal concerns.
Practical Compliance Guidance
At Lengea Law, we advise clients to approach peptides with clarity, not hype. Here is how:
- Do not assume peptides are permissible simply because competitors offer them.
- Audit your offerings before adding peptides to IV menus or wellness programs.
- Review marketing language carefully for implied therapeutic claims.
- Strengthen medical director agreements and protocols where peptides are involved.
- Get legal guidance early, before regulators get involved.
For practices considering or currently offering peptide-related services, compliance hinges on product quality, structure, transparency, and documentation. Any peptide use must be supported by clearly defined clinical protocols, active medical director oversight, and thorough informed consent processes that accurately describe the peptide’s regulatory status, including whether it is FDA-approved, compounded, or otherwise not approved for the intended use.
Strong internal policies, clear provider-delegation frameworks, and careful coordination with compliant compounding pharmacies are critical to reducing regulatory, licensing, and liability exposure in this evolving area.
The Bottom Line
Secretary Kennedy’s views on peptides have contributed to a broader discussion about healthcare innovation and access. However, even if Secretary Kennedy causes the FDA to pause enforcement against peptide compounders and sellers, state laws and regulations are still in effect. For now, at the state level, the legal standards have not changed. Medspas and healthcare providers should take Kennedy’s stance as an invitation to watch closely for policy developments, not as a signal that restrictions have already been lifted.
Additionally, unless federal agencies take concrete regulatory action or Secretary Kennedy implements a policy that pauses FDA enforcement, compliance with existing FDA law and guidance remains essential to protecting your professional licenses and business operations.
More importantly for providers, state licensing boards, particularly pharmacy boards in several states like Ohio, have taken a very active stance against research-use peptides. We are seeing investigations with settlements in the six figures and investigators pushing for revocation of providers’ licenses.
Staying compliant means understanding both the current rules and anticipatory shifts in federal posture. When in doubt, consulting knowledgeable legal counsel can help navigate this evolving space.
This article is for informational purposes only and does not constitute legal advice.